{"id":202668,"name":"VIATRIS INC","slug":"viatris-inc","state":"PA","description":"Pharmaceutical company","totalSpending":1270000,"filings":25,"yearlySpending":[{"year":2018,"income":30000},{"year":2019,"income":90000},{"year":2020,"income":200000},{"year":2021,"income":250000},{"year":2022,"income":210000},{"year":2024,"income":210000},{"year":2025,"income":280000}],"firms":["FEROX STRATEGIES"],"lobbyists":["CRISTINA ANTELO","LUCIA ALONZO","MARK WILLIAMS","DEBRA DIXON","MICHAEL TAGGART","ZACHARY FRIEND"],"issues":["CPT","HCR","TRD","PHA","FOR"],"sampleDescriptions":["Policy and oversight related to the generic pharmaceutical industry.","Policy and oversight related to the generic pharmaceutical industry\nH.R.2212/S. 974 - CREATES Act of 2017","Policy and oversight related to the generic pharmaceutical industry\nH.R.2212/S. 974 - CREATES Act of 2017\nH.R. 7251/S.3738 - Hatch-Waxman Integrity Act of 2018\nH.R.6294 - REVAMP Act","Issues related to intellectual property in the North American Free Trade Agreement","Policy and oversight related to the generic pharmaceutical industry\nH.R.965/S. 340 - CREATES Act of 2019","Issues related to intellectual property in the Unites States-Mexico-Canada Agreement","Issues related to drug pricing\nS.474 - Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019\nH.R.1499 - Protecting Consumer Access to Generic Drugs Act of 2019\nH.R.938 - BLOCKING Act of 2019\nH.R.1520 - Purple Book Continuity Act of 2019\nH.R.1503 - Orange Book Transparency Act of 2019\nH.R.2064 - To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes\nS.64 - Preserve Access to Affordable Generics and Biosimilars Act","Issues related to intellectual property in the United States-Mexico-Canada Agreement","Issues related to drug pricing\nH.R.1499 - Protecting Consumer Access to Generic Drugs Act of 2019\nH.R.938 - BLOCKING Act of 2019\nH.R.987 - Strengthening Health Care and Lowering Prescription Drug Costs Act\nH.R.965/S. 340 - CREATES Act of 2019\nH.R.2375/S. 64 - Preserve Access to Affordable Generics and Biosimilars Act\nH.R.2374/S. 1224 - Stop STALLING Act\nS.1895 - Lower Health Care Costs Act\nS.2103 - Affordable Insulin Approvals Now Act\nS.474 - Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019","Issues related to drug pricing\nH.R.1499 - Protecting Consumer Access to Generic Drugs Act of 2019\nH.R.938 - BLOCKING Act of 2019\nH.R.987 - Strengthening Health Care and Lowering Prescription Drug Costs Act\nH.R.965/S. 340 - CREATES Act of 2019\nH.R.2375/S. 64 - Preserve Access to Affordable Generics and Biosimilars Act\nH.R.2374/S. 1224 - Stop STALLING Act\nS.1895 - Lower Health Care Costs Act\nS.2103 - Affordable Insulin Approvals Now Act\nS.474 - Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019\nH.R.3 - Elijah E. Cummings Lower Drug Costs Now Act\nS.1416 - Affordable Prescriptions for Patients Act of 2019\nH.R.1865 - Further Consolidated Appropriations Act, 2020\nH.R.4913 - To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.","Issues related to intellectual property in the United States-Mexico-Canada Agreement\nS.3538 - Strengthening America's Supply Chain and National Security Act\nH.R.6201 - Families First Coronavirus Response Act\nH.R.748 - CARES Act","Issues related to drug pricing\nH.R.1499 - Protecting Consumer Access to Generic Drugs Act of 2019\nH.R.938 - BLOCKING Act of 2019\nH.R.987 - Strengthening Health Care and Lowering Prescription Drug Costs Act\nH.R.965/S. 340 - CREATES Act of 2019\nH.R.2375/S. 64 - Preserve Access to Affordable Generics and Biosimilars Act\nH.R.2374/S. 1224 - Stop STALLING Act\nS.1895 - Lower Health Care Costs Act\nS.2103 - Affordable Insulin Approvals Now Act\nS.474 - Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019\nH.R.3 - Elijah E. Cummings Lower Drug Costs Now Act\nS.1416 - Affordable Prescriptions for Patients Act of 2019\nH.R.1865 - Further Consolidated Appropriations Act, 2020\nH.R.4913 - To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.\nH.R.6179 - Increasing Access to Biosimilars Act of 2020\nH.R.6201 - Families First Coronavirus Response Act\nH.R.748 - CARES Act","Issues related to drug pricing \nIssues related to Medicaid Generics Penalty\nS.4134 - A bill to establish a demonstration project to increase access to biosimilar products under the Medicare program\nConsumer price index\nIssues related to workplace health and safety\nIssues related to the pharmaceutical supply chain\nH.R. 6395/S. 4049 - FY 2021 National Defense Authorization Act\nIssues related to federal COVID-19 response","Policy and oversight related to the generic pharmaceutical industry","Issues related to the pharmaceutical supply chain","Policy and oversight related to the generic pharmaceutical industry\nIssues related to the pharmaceutical supply chain\nIssues related to drug pricing\nIssues related to FDA generic drug approval process\nIssues related to Medicaid Generics Penalty\nIssues related to federal COVID-19 response\nS.4134 - A bill to establish a demonstration project to increase access to biosimilar products under the Medicare program\nIssues related to the consumer price index\nH.R. 6395/S. 4049 - FY 2021 National Defense Authorization Act","Policy and oversight related to the generic pharmaceutical industry\nIssues related to the pharmaceutical supply chain\nIssues related to drug pricing\nIssues related to FDA generic drug approval process\nIssues related to Medicaid Generics Penalty\nIssues related to federal COVID-19 response\nS.4134 - A bill to establish a demonstration project to increase access to biosimilar products under the Medicare program\nIssues related to the consumer price index\nH.R. 6395/S. 4049 - FY 2021 National Defense Authorization Act\nH.R.133 - Consolidated Appropriations Act, 2021","Policy and oversight related to the generic pharmaceutical industry. Issues related to the pharmaceutical supply chain. Issues related to drug pricing. Issues related to FDA generic drug approval process. Issues related to federal COVID-19 response. General issues related to Agriculture Appropriations.","Policy and oversight related to the generic pharmaceutical industry. Issues related to the pharmaceutical supply chain. Issues related to drug pricing. Issues related to FDA generic drug approval process. General issues related to Agriculture Appropriations.","Policy and oversight related to the generic pharmaceutical industry. Issues related to the pharmaceutical supply chain. Issues related to drug pricing. Issues related to FDA generic drug approval process."],"years":[2018,2019,2020,2021,2022,2024,2025]}